The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty (THA)
This study has been completed.
Sponsor:
Seoul National University Bundang Hospital
Information provided by:
Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT01098604
First received: April 1, 2010
Last updated: April 2, 2010
Last verified: March 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It has been postulated that use of a larger femoral head could reduce the risk of dislocation after total hip arthroplasty, but only limited clinical data have been presented in third generation alumina bearings.
The purpose of this study is to evaluate the effect of femoral head size for total hip arthroplasty using third generation alumina bearings on the joint stability and clinical results.
The investigators hypothesized that larger ceramic head group has a similar rate of dislocation and clinical results in smaller ceramic head group.
| Condition | Intervention | Phase |
|---|---|---|
|
Arthroplasty, Replacement, Hip |
Device: 32mm ceramic head group Device: 28mm ceramic head group |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty: A Randomized Clinical Trial |
Resource links provided by NLM:
Further study details as provided by Seoul National University Bundang Hospital:
Primary Outcome Measures:
- rate of dislocation in each head size [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
- rate of dislocation in each head size [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
- rate of dislocation in each head size [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
- rate of dislocation in each head size [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
- rate of dislocation in each head size [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
- rate of dislocation in each head size [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]to evaluate the null hypothesis that the dislocation rate of larger ceramic head group is similar to smaller ceramic head group.
Secondary Outcome Measures:
- clinical results using Harris Hip Score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
- clinical results using Harris Hip Score [ Time Frame: 3 months ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
- clinical results using Harris Hip Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
- clinical results using Harris Hip Score [ Time Frame: 9 months ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
- clinical results using Harris Hip Score [ Time Frame: 12 months ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
- clinical results using Harris Hip Score [ Time Frame: 24 months ] [ Designated as safety issue: No ]to compare the clinical results such as pain, function, range of motion between both groups.
| Enrollment: | 128 |
| Study Start Date: | May 2006 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 32mm ceramic head group
patients performed with THA using 32mm ceramic head
|
Device: 32mm ceramic head group
we performed THA using 32mm ceramic head in this group.
|
|
Active Comparator: 28mm ceramic head group
patients performed with THA using 28mm ceramic head
|
Device: 28mm ceramic head group
we performed THA using 28mm ceramic head in this group.
|
Eligibility| Ages Eligible for Study: | 20 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- osteonecrosis of femoral head
- primary or secondary osteoarthritis of the hips
- femoral neck fracture
Exclusion Criteria:
- previous hemi- or total hip arthroplasty
- highly dislocated or severe ankylosed hip
- patients who are considered potentially unreliable or who may not reliably attend study visits
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01098604
Locations
| Korea, Republic of | |
| Seoul national University Bundang Hospital | |
| Seongnam-Si, Gyeonggi-do, Korea, Republic of, 463-707 | |
Sponsors and Collaborators
Seoul National University Bundang Hospital
Investigators
| Principal Investigator: | Kyung-Hoi Koo, professor | Seoul National University Bundang Hospital |
More Information
No publications provided
| Responsible Party: | Kyung-Hoi, Koo/professor, Seoul National University Bundang Hospital |
| ClinicalTrials.gov Identifier: | NCT01098604 History of Changes |
| Other Study ID Numbers: | SNU 08-01 |
| Study First Received: | April 1, 2010 |
| Last Updated: | April 2, 2010 |
| Health Authority: | Korea: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 19, 2013